0
0
March 10, 2025 – A new study published in JAMA Network Open has revealed a significant association between the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and a reduced risk of certain hematologic cancers in patients with type 2 diabetes (T2D).
Researchers from Northeast Ohio Medical University conducted a retrospective cohort study, comparing the risks of hematologic cancers in T2D patients treated with GLP-1 RAs versus those treated with metformin and insulin. The study analyzed data from a large cohort of patients prescribed these medications between 2005 and 2023.
Key findings include:
- Reduced Risk:
- GLP-1 RA use was associated with significantly lower risks of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) compared to metformin use.
- When compared to insulin use, GLP-1 RA use showed a significantly reduced risk of a wider range of hematologic cancers, including myeloid leukemia, lymphoid leukemia, non-Hodgkin lymphoma, MDS, MPN, monoclonal gammopathy, multiple myeloma, and amyloidosis.
- GLP-1 RA use was associated with a 54 percent lower risk than that seen with insulin across all hematologic cancers.
- Study implications:
- The study suggests that GLP-1 RAs may offer a protective effect against the development of specific hematologic cancers in individuals with T2D.
The research indicates that the immunomodulatory features of GLP-1 RAs, along with weight loss, may contribute to this reduced risk. However, researchers also noted that metformin itself may have cancer-protective properties, which could explain why GLP-1RAs showed limited additional benefit against other cancers in the comparison to metformin.
The findings offer promising insights into the potential benefits of GLP-1 RAs beyond their established role in diabetes management. Further research is needed to fully understand the underlying mechanisms and to confirm these findings in larger, more diverse populations.
Disclaimer:
- The statistical data presented in this news article provides general trends and should not be interpreted as individual medical advice.
- Individual factors can vary significantly, and the results of this study may not apply to every person.
- Always consult with a qualified healthcare professional for personalized medical advice and before making any decisions related to your health or treatment.
- It is important to remember that medical research is always ongoing, and new information can change the current understanding.
